Valneva (NASDAQ:VALN) Price Target Lowered to $17.00 at HC Wainwright

Valneva (NASDAQ:VALN) had its price target lowered by HC Wainwright from $18.00 to $17.00 in a report published on Wednesday,Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Valneva’s Q4 2024 earnings at ($0.17) EPS, Q1 2025 earnings at ($0.40) EPS, Q2 2025 earnings at ($0.29) EPS, Q3 2025 earnings at ($0.33) EPS, Q4 2025 earnings at ($0.33) EPS, FY2025 earnings at ($1.36) EPS, FY2026 earnings at ($1.23) EPS and FY2027 earnings at ($1.28) EPS.

Valneva Price Performance

NASDAQ:VALN opened at $7.44 on Wednesday. Valneva has a 52 week low of $3.62 and a 52 week high of $9.50. The company has a quick ratio of 2.25, a current ratio of 2.78 and a debt-to-equity ratio of 0.70. The stock has a market capitalization of $604.58 million, a PE ratio of -57.23 and a beta of 1.98. The stock’s 50-day moving average price is $5.25 and its 200-day moving average price is $5.68.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. ABC Arbitrage SA purchased a new position in Valneva in the 4th quarter valued at about $84,000. AlphaCentric Advisors LLC lifted its stake in Valneva by 33.7% in the 3rd quarter. AlphaCentric Advisors LLC now owns 118,000 shares of the company’s stock valued at $717,000 after buying an additional 29,748 shares in the last quarter. Finally, Wells Fargo & Company MN lifted its stake in Valneva by 14.3% in the 4th quarter. Wells Fargo & Company MN now owns 246,766 shares of the company’s stock valued at $1,079,000 after buying an additional 30,859 shares in the last quarter. 11.39% of the stock is owned by hedge funds and other institutional investors.

About Valneva

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.